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ABSTRACT
The study determined the antipsychotic polypharmacy in selected Asian 
countries particularly Japan, Singapore, Korea, China, Taiwan, and Hongkong. 
This is a descriptive correlational study which utilized the clustering data mining 
technique. Data from the internet were gathered and analyzed using appropriate 
statistical management. Findings revealed that Japan and Singapore have the 
highest prevalence of antipsychotic polypharmacy. In terms of care settings, antipsychotic polypharmacy is prevalently high in both general hospitals and 
psychiatric facilities. Being male of increasing age and the duration of illness are 
directly proportional to the prevalence of antipsychotic polypharmacy.
I. INTRODUCTIONThe study dealt with issues and trends on antipsychotic polypharmacy among selected 
Asian countries. Polypharmacy pertains to the 
use of multiple medications by a single patient. When a patient uses two to four medications, it is termed minor polypharmacy while the use of more than four medications constitutes major 
polypharmacy. Psychotic symptoms are reported at a higher and varying rate in Asia (Chong, 2010) and antipsychotic medications are among 
the most common drugs being taken in multiple 
numbers by a single patient.According to Stibich (2010), the prescription of an alarming number of uncoordinated medications to a single patient constitutes 
polypharmacy. An individual patient, who is old and under the care of multiple physicians, may 
most likely experience polypharmacy (Hanlon, 
2007; Stibich, 2010). Antipsychotic polypharmacy in East Asia had been widely employed as a prescribing practice in the management of clients 
with psychotic symptoms (Sim, Su, Fujii, Yang, 
Chong, Ungvari, et.al 2004).The need to understand the trend in the practice of antipsychotic polypharmacy in different countries especially in Asia is a critical component in the management of psychotic 
disorders such as schizophrenia. Moreover, getting abreast with the prevalence of antipsychotic polypharmacy and aware of its related factors allow health care professionals to establish better 
medication regimen management. 
Given these, the researchers believe that it is necessary to be vigilant in this practice in order 
to make this management more acceptable as a 
treatment modality and decrease the likelihood of antipsychotic polypharmacy to generate more 
health-related problems in the future.
II. OBJECTIVESThis study determined the prevalence of antipsychotic polypharmacy and explored its 
related factors in selected Asian countries. 
Specifically, it sought the association of antipsychotic polypharmacy to patients in terms 
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of: (a) demographics; and (b) clinical factors. Finally, it aimed to identify recommendations to prevent health-related problems related to its 
practice.
III. CONCEPTUAL FRAMEwORKThe conduct of this study was based on the premise that medication regimen management 
practice is highly dynamic. The researchers believe that the mechanics of drug prescription 
can be attributed to a number of factors. Having this in mind, the researchers submit to the idea that pharmacologic approaches to treat psychotic 
symptoms can vary significantly. This holds 
true for polypharmacy. In trying to understand this concept, the authors attempt to uncover 
significant variables that can be related to the prescription of multiple medications to a single 
psychiatric patient. This is of substantial value as healthcare delivery system nowadays has greatly evolved into a more sophisticated but complex 
process. 
IV. REVIEw OF RELATED LITERATUREThe study of Xiang, Wang, Si, Lee, He, Ungvari, 
et.al in 2011 revealed that the proportion of antipsychotic polypharmacy prescription 
decreased from 46.8 % in 2001, to 38.3 % in 2004, 
and increased to 43.4 % in 2009, with wide inter-
country variations at each survey. The research used multiple logistic regression analysis of the entire sample which revealed that patients who 
most likely experience polypharmacy were young, and receiving higher dosage of neuroleptics especially those with more negative and positive 
symptoms. This implied that age and severity of illness have something to do with the occurrence 
of antipsychotic polypharmacy. A study using meta-analysis of nineteen 
(19) studies involving 1,229 subjects, revelaed that antipsychotic polypharmacy exhibited a 
significant advantage over monotherapy for 
psychotic patients in terms of efficacy and all-
cause discontinuation. Further, the simultaneous use of two neuroleptic agents appears to be 
more beneficial than adding a second drug to 
a concurrently used medication. Most of the positive studies were conducted in China (Correll, 
Rummel-Kluge, Corves, Kane, & Leucht, 2009).Previous studies of the prescription patterns of antipsychotic drugs in patients with psychotic 
disorders including schizophrenia have revealed 
widely variable rates (13–90%) of antipsychotic 
polypharmacy, defined as the use of more than 
one antipsychotic (Ito, Kubota, & Sato, 1999; 
Keks, Alton, & Hope, 1999; Weissman, 2002; Jaffe & Levine, 2003; Tapp, Wood, Secrest, Erdmann, 
Cubberley, & Kilzieh, 2003). The wide variation in the rates of combination antipsychotic therapy between countries has been attributed to differences in healthcare systems affecting availability and economic cost of antipsychotics (McCombs, Nichol, Johnstone, Stimmel, Shi, & Smith, 2000), local prescription traditions and culture as well as personal experience and choice 
(Fleischhacker, 2003). The higher rates of antipsychotic polypharmacy may be related to the treatment setting, since a psychiatric hospital has a higher 
likelihood of admitting more seriously ill patients compared with a general hospital psychiatric 
unit. The combination of more than one antipsychotic may be an attempt at preventing the rapid escalation of the dose of any single 
medication (Freudenreich, & Goff, 2002) or as an alternative towards the management of treatment unresponsiveness or partial response (Stahl, 
2002). 
V. DESIGN AND METHODSThe study used a descriptive correlational design to establish an association between the prevalence of polypharmacy and its impact on the 
different factors. It also used comparative design 
to find out for a significant difference in the extent that polypharmacy impacts on the countries in 
terms of gender and treatment setting. Data were gathered from internet sources particularly US National Library of Medicine- National Institute of Health and Online British 
75
Journal. The database contains more than 21.6 
million records from 5,582 selected publications 
covering biomedicine and health from 1950 to the present and facilitates evidenced-based 
medicines. Articles published here are built on 
extensive searches to make the findings useful 
and meaningful.The variables in this study were (1) prevalence, measured in terms of percentage per population who experienced antipsychotic polypharmacy in a certain Asian country; (2) demographics, measured in terms of age and gender; and (3) clinical factors, measured in terms of the duration of illness, use of anticholinergic 
drugs, and treatment setting.
Data mining techniques that was utilized in this study was clustering in order to group 
variables based on certain characteristics. It was 
employed to generate tentative generalizations and theories based on the groupings of certain 
variables.  
VI. RESULTS AND DISCUSSIONThe table presents the prevalence of antipsychotic polypharmacy (APP) in the six 
Asian countries in terms of percentage. It also shows the data on demographics (age, gender) as well as clinical factors (DOI, ACU, treatment 
settings) that could influence or be associated 
with the antipsychotic polypharmacy prevalence.
Country APPPa Age Male Female DOIb ACU GenHosp PsychSettingJapan 78.6 52.9 58.4 41.6 65.8 50.4 78 78.1Singapore 70.3 46.2 58.7 41.3 32 6.7 82 100Korea 35.5 39.1 57 43 17.7 37.1 76 38.7China 25.2 38.5 50.9 49.1 28.1 64 34.7 67.3Taiwan 22.2 38.2 55.6 44.4 25.7 48.6 61.4 100
Hongkong 12 45.4 58.3 41.7 52.8 46.3 50 100
a Antipsychotic Polypharmacy Prevalence
b Duration of Illness (>20 years)
c Anticholinergic Use
Table 1. Data	Distribution
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As seen in the table, Japan and Singapore have the highest prevalence of antipsychotic polypharmacy as compared to the four other 
countries. Relevant to the development of these nations, it is not surprising that those psychotic patients from these areas experience polypharmacy practically because of the fact that they are capable of purchasing multiple 
medications. The average age at which patients experience antipsychotic polypharmacy in these nations appear to be also higher as compared 
to other nations. Still with Japan and Singapore, 
males are more likely to experience this health-related issue which is contrary to their female 
counterparts. This is also true with Hongkong. The other three countries—China, Korea, and Taiwan, with lower antipsychotic polypharmacy 
prevalence have higher female gender 
involvement. In terms of duration of illness, Japan 
and Hongkong have the most number of patients whose illness have been existing for more than 20 
years. As for the use of anticholinergics, Singapore 
appears to have a significantly lower percentage 
compared to the other five nations. Because those drugs counteract antipsychotic adverse reactions, the use of these agents possibly, though not 
conclusively, induced an influence on Singapore’s 
antipsychotic polypharmacy prevalence. On treatment settings, more antipsychotic polypharmacy incidences were experienced by patients in the psychiatric facility as compared to 
those in the general hospitals. The table below presents the results of data 
analysis using multivariate clustering. This was done in order to group the countries according to 
some similar characteristics.  
Variable Cluster1 Cluster2 Grand centroidAPPP 74.45 23.725 40.6333Age 49.55 40.3 43.3833Male 58.55 55.45 56.4833Female 41.45 44.55 43.5167DOI 48.9 31.075 37.0167ACU 28.55 49 42.1833HospSetting 80 55.525 63.6833PsychSetting 89.05 76.5 80.6833
Table 2. Cluster	Analysis
As observed in the table, cluster 1 consists of countries with high prevalence of antipsychotic polypharmacy namely Japan and Singapore while cluster 2 countries are those with lower percentages of antipsychotic polypharmacy 
prevalence specifically Korea, China, Taiwan and 
Hongkong. Clusters 1 composed of countries with demanding lifestyle due to the nature of their jobs, economic advancement and have the tendency to 
encounter stressful activities. These activities are 
77
one of the contributing factors which can affect the psychological performance of a person resulting to 
the use of antipsychotic drugs.  The data revealed that clustered developed countries, practiced APP 
due to remarkable sources of funds  hence can afford to spend costly effective medicines and 
very much influenced on the therapeutic effects of polypharamcy because of advance information in 
medicine.  While cluster 2, as poor countries they have the tendency to purchase cheaper drugs which may have higher side effects that require the use of another anticholinergic drugs, thus the 
rate of ACU is high.  They have limited information on the advancement of medicine and not very 
much influenced of multiple drug combination 
specifically related to polypharmacy.  The use of anticholinergic drug for most developed countries are low since the costly effective medicines used, exhibit lesser side effects hence do not require 
another anticholinergic drugs for its side effects.
The findings revealed that as age increases, the antipsychotic polypharmacy prevalence also 
increases. This implies that the older one gets, the 
more likely he/she be required to take multiple 
medications to treat psychotic symptoms. This is due to long term use of drugs producing multiple side effects and it is where other medications 
are again required for such new side effects. ‘Stable’ patients with psychosis, receiving long-term antipsychotic monotherapy, may develop an acute exacerbation of psychotic symptoms, or worsening of agitation or insomnia and be prescribed an additional antipsychotic on an 
‘as required’ or short-term basis. However, such short-term or ‘as required’ prescriptions may develop into medium- or long-term adjuvant treatments, particularly if considered successful 
in the short term. A natural reluctance to risk a recurrence of symptoms tends to perpetuate this situation and ultimately results in long-term antipsychotic polypharmacy (Langan & Shajahan, 2010)In cluster 1, being male also dictates an increase in the antipsychotic polypharmacy prevalence 
than cluster 2.  The demand of lifestyle, nature of 
jobs, economic and technological advancement plays an important role to the deleterious health 
status of people in Japan and Singapore. It is more prevalent on psychological effects rather than in other illnesses, thus the need of polypharmacy is more common in developed countries due to 
greater responsibility in the society. With this, 
it also signifies that gender has an impact on 
the prevalence of antipsychotic polypharmacy. Another is, receptor interaction follows 
therapeutic pattern in terms of pharmacokinetic response, male require higher dose of drugs since dosage requirement is based on weights of the 
person and surface area of the body (Katzung, 
2010).  Most males are structurally bigger than the females, with this, male require more APP 
than female.  In cluster 2, the role of female in cultural, domestic and pattern of responsibility 
is highly emphasized in poor countries resulting to psychological manifestations among female, 
hence tend to use APP than in cluster 1.Further, the phenomenon increases 
significantly with longer duration of illness which means that the longer the illness persists and the more it becomes chronically severe, it would necessitate the use of more neuroleptic 
medications.  When clinicians aim to switch their patients from one antipsychotic to another by cross-tapering, the switch may never be fully 
completed as symptoms stabilize or improve. This leads to reluctance on the part of clinician or patient to complete the switch and may postpone 
the completion of the switch indefinitely, leading to long-term antipsychotic polypharmacy 
(Langan & Shajahan, 2010).   A study conducted 
in Tokyo, showed longer duration of illness and lower subjective distress caused by side effects were predictive for a more favorable subjective 
response to medication. On the other hand, female gender, younger age, and lower BPRS score were independently correlated with a positive 
subjective response to medication in Beijing. Total variance explained by the regression model was 
27% for the Tokyo group and 35% for the Beijing 
group (Kuroda et. al.).  
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jobs, economic and technological advancement plays an important role to the deleterious health 
status of people in Japan and Singapore. It is more prevalent on psychological effects rather than in other illnesses, thus the need of polypharmacy is more common in developed countries due to 
greater responsibility in the society. With this, 
it also signifies that gender has an impact on 
the prevalence of antipsychotic polypharmacy. Another is, receptor interaction follows 
therapeutic pattern in terms of pharmacokinetic response, male require higher dose of drugs since dosage requirement is based on weights of the 
person and surface area of the body (Katzung, 
2010).  Most males are structurally bigger than the females, with this, male require more APP 
than female.  In cluster 2, the role of female in cultural, domestic and pattern of responsibility 
is highly emphasized in poor countries resulting to psychological manifestations among female, 
hence tend to use APP than in cluster 1.Further, the phenomenon increases 
significantly with longer duration of illness which means that the longer the illness persists and the more it becomes chronically severe, it would necessitate the use of more neuroleptic 
medications.  When clinicians aim to switch their patients from one antipsychotic to another by cross-tapering, the switch may never be fully 
completed as symptoms stabilize or improve. This leads to reluctance on the part of clinician or patient to complete the switch and may postpone 
the completion of the switch indefinitely, leading to long-term antipsychotic polypharmacy 
(Langan & Shajahan, 2010).   A study conducted 
in Tokyo, showed longer duration of illness and lower subjective distress caused by side effects were predictive for a more favorable subjective 
response to medication. On the other hand, female gender, younger age, and lower BPRS score were independently correlated with a positive 
subjective response to medication in Beijing. Total variance explained by the regression model was 
27% for the Tokyo group and 35% for the Beijing 
group (Kuroda et. al.).  
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such short-ter  or ‘as required’ prescriptions 
may develop into medium- or long-term adjuvant 
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recurrence  of  symptoms  tends  to  perpetuate 
this situation and ultimately results in long-term 
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prevalence than cluster 2. The demand of lifestyle, 
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Finally, the treatment locations, particularly psychiatric setting, also increase the antipsychotic 
polypharmacy prevalence. In cluster 1, developed 
countries are more particular of confinements due to readily available funds and advance understanding of medicine, while cluster 2 most especially in China they will supplement or employ alternative medicine, thus hospital setting would 
not be more preferable.  A study was conducted 
on “Attitudes toward taking medication among 
outpatients with schizophrenia: cross-national 
comparison between Tokyo and Beijing” showed that, years of education and total length of 
hospitalization were significantly longer for 
subjects in Tokyo.  In addition, samples were 
significantly different in regards to health 
economic resources; all subjects in Tokyo had 
health insurance, whereas only 25% of the 
subjects in Beijing had insurance (Kuroda et. al.). 
Cultural beliefs can also influence the decisions of 
confinements in China, Korea and Taiwan. This implied that in-patients (admitted 
patients) are more likely to experience antipsychotic polypharmacy in psychiatric 
facilities.  In most admitted patients, they are exposed to APP because of some complications 
that may likely to occur while existing APP drugs 
are in used.  If complication occur specialized doctors are needed and another drugs may be prescribed that will contribute to the use of 
polypharmacy drugs. 
VII. CONCLUSION
Financial resources greatly influence the 
health needs of a person.  If more financial funds are available, the more drugs can be provided for 
its treatment. Countries like Japan, Singapore, China and Korea being developed countries with 
high financial resources have high APP prevalence.
There are factors that influence APP most especially the demographic and clinical 
profile of the patients.  The prevalence of antipsychotic polypharmacy is associated with 
both demographic and clinical factors. This 
is of important consideration for health care professionals in order for them to establish psychiatric management holistically, paying 
significant attention to demographic and clinical 
variables.
REFERENCES
Correll,	C.U.,	Rummel-Kluge,	C.,	Corves,	C.,	Kane,	J.M.,	
&	Leucht,	S.	(2009).	Antipsychotic	combinations	
versus	 monotherapy	 in	 schizophrenia:	 A	
meta-analysis	 of	 randomized	 controlled	 trials.	
Schizophrenia Bulletin,	35(2),	443-457.
Freudenreich,	 O.,	 Goff,	 D.C.	 (2002).	 Antipsychotic	
combination	therapy	in	schizophrenia.	A	review	
of	 efficacy	 and	 risks	 of	 current	 combinations.	
Acta Psychiatrica Scandinavica,	106(5),	323-30. 
Ito,	 C.,	 Kubota,	 Y.,	 &	 Sato,	 M.	 (1999).	 A	 prospective	
survey	 on	 drug	 choice	 for	 prescriptions	 for	
admitted	patients	with	schizophrenia.	Psychiatry 
and Clinical Neurosciences,	53(1),	S35-S40.	
Katzung	(2010).	Antidepressants:		Katzung	(2010)	review.	
The Feria Journal of Medicine.	Rerieved	 from	
http://theferiajournalofmedicine.blogspot.
com/2010/10/antidepressants-katzung-2010-
review.html
Keks,	 N.A.,	 Altson,	 K.,	 Hope,	 J.,	 et	 al	 (1999).	 Use	 of	
antipsychosis	 and	 adjunctive	 medications	 by	
an	 inner	 urban	 community	 psychiatric	 service.	
Australian and New Zealand Journal of 
Psychiatry, 33(1),	896-901.
Langan,	 J.,	 &	 Shajahan,	 P.	 (2010).	 Antipsychotic	
polypharmacy:	 Review	 of	 mechanisms,	
mortality	and	management.	Psychiatric Bulletin,	
34(1).	58-62.	doi:	10.1192/pb.bp.108.024257
McCombs,	J.S.,	Nichol,	M.B.,	Johnstone,	B.M.,	Stimmel,	
G.L.,	Shi,	J.,	&	Smith,	R.	(2000).	Antipsychotic	
drug	 use	 patterns	 and	 the	 cost	 of	 treating	
schizophrenia.	Psychiatric	Services.	51(4),	525-
527.
Sim,	 K.,	 Su,	A.,	 Fujii,	 S.,	 Yang,	 S.Y.,	 Chong,	 M.Y.,	 et	
al.	 (2004).	 Antipsychotic	 polypharmacy	 in	
patients	 with	 schizophrenia:	 A	 multicentre	
comparative	study	in	East	Asia.	British Journal 
of Clinical Pharmacology,	58(1),	178–183.	doi:	
10.1111/j.1365-2125.2004.02102.x
Tapp,	A.,	Wood,	A.E.,	Secrest,	L.,	Erdmann,	J.,	Cubberley,	
L.,	 &	 Kilzieh,	 N.	 (2003).	 Combination	
originality index:  91 %   
similarity index:   1 % 
paper id:   470234427
Grammarly:   checked
79
antipsychotic	 therapy	 in	 clinical	 practice.	
Psychiatric Services,	54(1),	55-59.	doi:	10.1176/
appi.ps.54.1.55-59
Xiang,	Y.T.,	Wang,	 C.Y.,	 Si,	 T.M.,	 Lee,	 E.H.,	 He,	Y.L.,	
Ungvari,	 G.S.,	 et	 al.	 (2011).	 Clozapine	 use	 in	
schizophrenia:	Findings	of	the	research	on	Asia	
Psychotropic	Prescription	(REAP)	studies	from	
2001	 to	 2009.	 Australian and  New Zealand 
Journal of  Psychiatry,	45(1),	968–975.
Yaun, E. A. and Sacramento, S.  B.
   
.   In iti , 
iff t with regard t  
i , hereas only 25  f 
in Beijing had insurance (Kuroda et
al., n.d.). Cultural beliefs can also influence the
decisions of confinements in China, Korea and 
Taiwan.
Thi  implies that in-patients (admitted
pa ents) are more likely to experience antipsychot
polypharmacy in psychiatric facilitie . In most
admitted patients, they are exposed to APP because
of so e complicati ns that may l kely occur while
exist g APP drugs are in used. If complic t ons
occur, pecialized doctors re ne de  and another
d ugs may be prescribed that will contribute to the
use of polypharmacy drugs.
 .  
, a   i  
UV Journal  of  Research78
Finally, the treatment locations, particularly psychiatric setting, also increase the antipsychotic 
polypharmacy prevalence. In cluster 1, developed 
countries are more particular of confinements due to readily available funds and advance understanding of medicine, while cluster 2 most especially in China they will supplement or employ alternative medicine, thus hospital setting would 
not be more preferable.  A study was conducted 
on “Attitudes toward taking medication among 
outpatients with schizophrenia: cross-national 
comparison between Tokyo and Beijing” showed that, years of education and total length of 
hospitalization were significantly longer for 
subjects in Tokyo.  In addition, samples were 
significantly different in regards to health 
economic resources; all subjects in Tokyo had 
health insurance, whereas only 25% of the 
subjects in Beijing had insurance (Kuroda et. al.). 
Cultural beliefs can also influence the decisions of 
confinements in China, Korea and Taiwan. This implied that in-patients (admitted 
patients) are more likely to experience antipsychotic polypharmacy in psychiatric 
facilities.  In most admitted patients, they are exposed to APP because of some complications 
that may likely to occur while existing APP drugs 
are in used.  If complication occur specialized doctors are needed and another drugs may be prescribed that will contribute to the use of 
polypharmacy drugs. 
VII. CONCLUSION
Financial resources greatly influence the 
health needs of a person.  If more financial funds are available, the more drugs can be provided for 
its treatment. Countries like Japan, Singapore, China and Korea being developed countries with 
high financial resources have high APP prevalence.
There are factors that influence APP most especially the demographic and clinical 
profile of the patients.  The prevalence of antipsychotic polypharmacy is associated with 
both demographic and clinical factors. This 
is of important consideration for health care professionals in order for them to establish psychiatric management holistically, paying 
significant attention to demographic and clinical 
variables.
REFERENCES
Correll,	C.U.,	Rummel-Kluge,	C.,	Corves,	C.,	Kane,	J.M.,	
&	Leucht,	S.	(2009).	Antipsychotic	combinations	
versus	 monotherapy	 in	 schizophrenia:	 A	
meta-analysis	 of	 randomized	 controlled	 trials.	
Schizophrenia Bulletin,	35(2),	443-457.
Freudenreich,	 O.,	 Goff,	 D.C.	 (2002).	 Antipsychotic	
combination	therapy	in	schizophrenia.	A	review	
of	 efficacy	 and	 risks	 of	 current	 combinations.	
Acta Psychiatrica Scandinavica,	106(5),	323-30. 
Ito,	 C.,	 Kubota,	 Y.,	 &	 Sato,	 M.	 (1999).	 A	 prospective	
survey	 on	 drug	 choice	 for	 prescriptions	 for	
admitted	patients	with	schizophrenia.	Psychiatry 
and Clinical Neurosciences,	53(1),	S35-S40.	
Katzung	(2010).	Antidepressants:		Katzung	(2010)	review.	
The Feria Journal of Medicine.	Rerieved	 from	
http://theferiajournalofmedicine.blogspot.
com/2010/10/antidepressants-katzung-2010-
review.html
Keks,	 N.A.,	 Altson,	 K.,	 Hope,	 J.,	 et	 al	 (1999).	 Use	 of	
antipsychosis	 and	 adjunctive	 medications	 by	
an	 inner	 urban	 community	 psychiatric	 service.	
Australian and New Zealand Journal of 
Psychiatry, 33(1),	896-901.
Langan,	 J.,	 &	 Shajahan,	 P.	 (2010).	 Antipsychotic	
polypharmacy:	 Review	 of	 mechanisms,	
mortality	and	management.	Psychiatric Bulletin,	
34(1).	58-62.	doi:	10.1192/pb.bp.108.024257
McCombs,	J.S.,	Nichol,	M.B.,	Johnstone,	B.M.,	Stimmel,	
G.L.,	Shi,	J.,	&	Smith,	R.	(2000).	Antipsychotic	
drug	 use	 patterns	 and	 the	 cost	 of	 treating	
schizophrenia.	Psychiatric	Services.	51(4),	525-
527.
Sim,	 K.,	 Su,	A.,	 Fujii,	 S.,	 Yang,	 S.Y.,	 Chong,	 M.Y.,	 et	
al.	 (2004).	 Antipsychotic	 polypharmacy	 in	
patients	 with	 schizophrenia:	 A	 multicentre	
comparative	study	in	East	Asia.	British Journal 
of Clinical Pharmacology,	58(1),	178–183.	doi:	
10.1111/j.1365-2125.2004.02102.x
Tapp,	A.,	Wood,	A.E.,	Secrest,	L.,	Erdmann,	J.,	Cubberley,	
L.,	 &	 Kilzieh,	 N.	 (2003).	 Combination	
originality index:  91 %   
similarity index:   1 % 
paper id:   470234427
Grammarly:   checked
79
antipsychotic	 therapy	 in	 clinical	 practice.	
Psychiatric Services,	54(1),	55-59.	doi:	10.1176/
appi.ps.54.1.55-59
Xiang,	Y.T.,	Wang,	 C.Y.,	 Si,	 T.M.,	 Lee,	 E.H.,	 He,	Y.L.,	
Ungvari,	 G.S.,	 et	 al.	 (2011).	 Clozapine	 use	 in	
schizophrenia:	Findings	of	the	research	on	Asia	
Psychotropic	Prescription	(REAP)	studies	from	
2001	 to	 2009.	 Australian and  New Zealand 
Journal of  Psychiatry,	45(1),	968–975.
Yaun, E. A. and Sacramento, S.  B.
81Psychosocial determinants of corruption
Queen Heneylour S. Relatorres, CSP
Maguindah Lumarog Nemenzo
Jonalyn G. Nalzaro
University of the Visayas
drelatorres@gmail.com
Date Submitted: March 15, 2014 Date accepted: October 18, 2014
ABSTRACT
Psychosocial determinants of corruption was recommended in order to give emphasis that corruption is innate in nature in which discontentment and security 
takes place as a motivating factor, why a certain person committed corruption, it 
involves Maslow’s Hierarchy of needs which determines the self-actualization as the higher needs of man or a belief that he/she was fully used all their potentials 
as a result of  full satisfaction .  In Sociological and  Psychological Perspective, man has its own individual characteristics, ability to perceive what is right and what 
is wrong,  as well as the ability to observe and adopt what is being observed.  As determinants of corruption two (2) theories are involve anchored by Bandura’s 
observation Learning Theory .  (1)The Freudian theory which asserts man Id , ego and super –ego and the (2) second theory eventually imitate observable anti-
social acts that would immediately satisfy their needs . Derived propositions are the following: (1) People with low sense of guilt will eventually imitate observable anti-social acts that would immediately satisfy their needs  (2) Some people prefer to commit corrupt acts because it has greater payoff but with less threat on legal 
punishment.( 3) Individual with great sense of his moral conscience can achieve 
self-actualization. (4) Actualized People will never engage in corruption. (5) Self-
actualized people are Incorruptible. 
Keywords: psychosocial, corruption, self-actualizer
I. INTRODUCTIONCorruption is one of the primary problem and concern in many under developed and developing 
nations. Substantial portion of funds allocated to spur social and economic activities in the countries 
are siphoned into the pockets of few individuals, thus resulting into sub standards delivery of goods and service in the countries The United Nations 
(2009) estimated that roughly 25 % of the national budgets of countries listed as among those with high corruption incidences remains unaccounted for and end up in the personal custody of highly 
authoritative individuals. While governments of the countries have passed laws and ordinances imposing stiff sanction on individuals convicted for corruption, the situation has essentially remained 
the same over the years. Government interventions that target the symptoms of corruption rather than the cause of corruption are and will always remain in 
effective.  The dimension of corruption committed in the sphere of the legal economy are possibly obvious but that may, indeed be seen to be more reason for 
the study of corruption on the interactional level. This paper attempts to explain the psycho-social 
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